ZA200502384B - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors Download PDF

Info

Publication number
ZA200502384B
ZA200502384B ZA200502384A ZA200502384A ZA200502384B ZA 200502384 B ZA200502384 B ZA 200502384B ZA 200502384 A ZA200502384 A ZA 200502384A ZA 200502384 A ZA200502384 A ZA 200502384A ZA 200502384 B ZA200502384 B ZA 200502384B
Authority
ZA
South Africa
Prior art keywords
alkyl
substituted
compound
halogen
optionally substituted
Prior art date
Application number
ZA200502384A
Other languages
English (en)
Inventor
Girardet Jean-Luc
Hamatake Robert
Gunic Esmir
Kim Hong Woo
Nilar Shahul
Yao Nanhua
Zhang Zhijun
La Rosa Martha A De
Hong Zhi
Koh Yung-Liyo
Shaw Stephanie
Original Assignee
Valeant Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Res & Dev filed Critical Valeant Res & Dev
Publication of ZA200502384B publication Critical patent/ZA200502384B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA200502384A 2002-08-23 2005-03-22 Non-nucleoside reverse transcriptase inhibitors ZA200502384B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US0226816 2002-08-23

Publications (1)

Publication Number Publication Date
ZA200502384B true ZA200502384B (en) 2007-03-28

Family

ID=32067653

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200502384A ZA200502384B (en) 2002-08-23 2005-03-22 Non-nucleoside reverse transcriptase inhibitors

Country Status (13)

Country Link
US (2) US20060135556A1 (https=)
EP (2) EP2353593B1 (https=)
JP (1) JP4413781B2 (https=)
CN (1) CN1697650B (https=)
AT (1) ATE504294T1 (https=)
AU (2) AU2003295324B2 (https=)
BR (1) BR0313747A (https=)
CA (1) CA2496565C (https=)
DE (1) DE60336664D1 (https=)
EA (1) EA009478B1 (https=)
MX (1) MXPA05002070A (https=)
WO (1) WO2004030611A2 (https=)
ZA (1) ZA200502384B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030611A2 (en) * 2002-08-23 2004-04-15 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
EP1723123A4 (en) * 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
US7517998B2 (en) * 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
DK2135608T3 (da) * 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
KR20110089463A (ko) * 2006-07-24 2011-08-08 한국화학연구원 신규 hiv 역전사 효소 억제제
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2736117C (en) * 2008-09-04 2013-11-19 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
AU2010307262A1 (en) 2009-07-10 2012-03-01 Microbiotix, Inc. Inhibitors of filovirus entry into host cells
MX2012015097A (es) * 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
CN101899013B (zh) * 2010-07-12 2012-07-25 山东大学 2-(2-取代芳基-2h-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用
CN105394046B (zh) 2010-10-25 2019-03-01 范德比尔特大学 用于抑制昆虫宿主感觉的组合物
US9578881B2 (en) 2011-05-06 2017-02-28 Vanderbilt University Compositions for inhibition of insect sensing
ITMI20120786A1 (it) * 2012-05-09 2013-11-10 Fond Italiana Sclerosi M Ultipla Fism Onlu Modulatori del recettore gpr17
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
RU2626003C2 (ru) * 2014-04-28 2017-07-21 Общество с ограниченной ответственностью "Квантум Фармасьютикалс" Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа
EP3273779A4 (en) 2015-03-25 2018-09-05 Vanderbilt University Binary compositions as disruptors of orco-mediated odorant sensing
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0759563B2 (ja) * 1987-01-28 1995-06-28 大塚化学株式会社 ピラゾ−ル誘導体、その製造方法及び該誘導体を有効成分とする除草剤
EP0303301A3 (en) * 1987-08-14 1989-05-17 Fuji Photo Film Co., Ltd. Silver halide photographic material
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Hiv를 억제하는 피리미딘 유도체
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
AU2002254056C1 (en) 2001-03-02 2006-04-13 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
WO2004030611A2 (en) * 2002-08-23 2004-04-15 Ribapharm Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20060205026A1 (en) * 2002-12-19 2006-09-14 Valeant Research & Development Parallel inducible cell-based kinase screen
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US7842836B2 (en) * 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5269762B2 (ja) * 2006-04-18 2013-08-21 アーディア・バイオサイエンシーズ・インコーポレイテッド Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
EP2132211A4 (en) * 2006-11-09 2011-12-07 Ardea Biosciences Inc 4-CYANPHENYLAMINO-SUBSTITUTED BICYCLIC AND HETEROCYCLIC COMPOUNDS AS AN HIV HEMMER

Also Published As

Publication number Publication date
CN1697650A (zh) 2005-11-16
AU2008246249B2 (en) 2010-09-30
ATE504294T1 (de) 2011-04-15
AU2003295324A1 (en) 2004-04-23
US20060135556A1 (en) 2006-06-22
EP1545483B1 (en) 2011-04-06
BR0313747A (pt) 2005-06-21
EP1545483A2 (en) 2005-06-29
EP1545483A4 (en) 2009-03-25
EA200500399A1 (ru) 2005-12-29
AU2008246249A1 (en) 2008-12-11
EA009478B1 (ru) 2008-02-28
CA2496565A1 (en) 2004-04-15
CA2496565C (en) 2013-04-02
JP2006505543A (ja) 2006-02-16
EP2353593B1 (en) 2012-08-22
JP4413781B2 (ja) 2010-02-10
HK1085667A1 (en) 2006-09-01
WO2004030611A2 (en) 2004-04-15
MXPA05002070A (es) 2005-07-05
WO2004030611A3 (en) 2004-06-17
DE60336664D1 (de) 2011-05-19
AU2003295324B2 (en) 2008-08-28
EP2353593A1 (en) 2011-08-10
US20080249131A1 (en) 2008-10-09
CN1697650B (zh) 2010-11-10

Similar Documents

Publication Publication Date Title
ZA200502384B (en) Non-nucleoside reverse transcriptase inhibitors
US11267801B2 (en) Therapeutic compounds
AU2015371255B2 (en) Fused pyrimidine compounds for the treatment of HIV
US9624195B2 (en) Isoquinoline compounds
US9873680B2 (en) Therapeutic compounds
EP3409667B1 (en) Amide compounds for the treatment of hiv infections
JP5372751B2 (ja) Aza−ペプチドプロテアーゼ阻害剤
CN118477088A (zh) N4-羟基胞苷及衍生物和与其相关的抗病毒用途
JP2002540156A (ja) 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体
JP4121151B2 (ja) 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
JP2013151559A (ja) 抗ウイルスプロテアーゼインヒビター
US20090312324A1 (en) Compositions and Methods Related to RAD51 Inactivation in the Treatment of Neoplastic Diseases, and Especially CML
CA2211920A1 (en) Anti-viral triaza compounds
WO2011116287A1 (en) Ccr5 modulators for treating hiv
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
US8669248B1 (en) Adenine inhibitors of HSP90
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
US20250188083A1 (en) Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof
AU2022210451A1 (en) Compounds and methods for treating malaria
WO2026015819A1 (en) Trdmt1 inhibitors
HK1085667B (en) Non-nucleoside reverse transcriptase inhibitors
WO2004018427A1 (en) O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives